| |
| | Long-term Azithromycin Helps Children With CF |
 | | A macrolide antibiotics ability to enhance survival in a similar lung condition prompted researchers to test long-term azithromycin therapy in children with CF.[1] Compared with placebo, azithromycin (250 to 500 mg/d for four to six months) significantly improved forced expiratory volume in one second (FEV1) and reduced the number of additional antibiotics prescribed. |
 | | Azithromycin, on a long-term basis, provides a significant benefit to a sufficiently large number of children to merit its use as a treatment in those who are not responding to conventional agents, said Mark Rosenthal, FRCPCH, consultant in pediatric respiratory medicine at Royal Brompton Hospital, London. |
 | | Azithromycin treatment alone yielded improvement over placebo in FEV1, FVC, and mid-expiratory flow (median differences, 11.5%, 7.3%, and 21.9%, respectively), but azithromycin with simultaneous DNAse treatment did not (median differences, 3.6%, 4.5%, and 9.5%, respectively). |
| www.pulmonaryreviews.com /dec02/pr_dec02_azithromycin.html (477 words) |
|